Dear Christine Cappa:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement for the FoundationOne® CDx (F1CDx) to include a companion diagnostic indication for FGFR2 fusions and select rearrangements in cholangiocarcinoma patients who may benefit from treatment with Pemazyre® (pemigatinib). This device is indicated for the following:

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels) and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for cancer patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Biomarker(s) Detected</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-small cell lung cancer (NSCLC)</td>
<td>EGFR exon 19 deletions and EGFR exon 21 L858R alterations</td>
<td>Gilotrif® (afatinib), Iressa® (gefitinib), Tagrisso® (osimertinib), or Tarceva® (erlotinib)</td>
</tr>
<tr>
<td></td>
<td>EGFR exon 20 T790M alterations</td>
<td>Tagrisso® (osimertinib)</td>
</tr>
</tbody>
</table>
ALK rearrangements

<table>
<thead>
<tr>
<th>ALK rearrangements</th>
<th>Alecensa® (alectinib), Xalkori® (crizotinib), or Zykadia® (ceritinib)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BRAF V600E</strong></td>
<td>Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib)</td>
</tr>
</tbody>
</table>

**Melanoma**

<table>
<thead>
<tr>
<th><strong>BRAF V600E</strong></th>
<th>Tafinlar® (dabrafenib) or Zelboraf® (vemurafenib)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BRAF V600E and V600K</strong></td>
<td>Mekinist® (trametinib) or Cotellic® (cobimetinib) in combination with Zelboraf® (vemurafenib)</td>
</tr>
</tbody>
</table>

**Breast cancer**

<table>
<thead>
<tr>
<th><strong>ERBB2 (HER2) amplification</strong></th>
<th>Herceptin® (trastuzumab), Kadcyla® (ado-trastuzumab-emtansine), or Perjeta® (pertuzumab)</th>
</tr>
</thead>
</table>

**Colorectal cancer**

<table>
<thead>
<tr>
<th><strong>KRAS</strong> wild-type (absence of mutations in codons 12 and 13)</th>
<th>Erbitux® (cetuximab)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>KRAS</strong> wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)</td>
<td>Vectibix® (panitumumab)</td>
</tr>
</tbody>
</table>

**Ovarian cancer**

<table>
<thead>
<tr>
<th><strong>BRCA1/2 alterations</strong></th>
<th>Lynparza® (olaparib) or Rubraca® (rucaparib)</th>
</tr>
</thead>
</table>

**Cholangiocarcinoma**

| **FGFR2 fusions and select rearrangements** | Pemazyre™ (pemigatinib) |

The test is also used for detection of genomic loss of heterozygosity (LOH) from formalin-fixed, paraffin-embedded (FFPE) ovarian tumor tissue. Positive homologous recombination deficiency (HRD) status (F1CDx HRD defined as tBRCA-positive and/or LOH high) in ovarian cancer patients is associated with improved progression-free survival (PFS) from Rubraca (rucaparib) maintenance therapy in accordance with the RUBRACA product label.

The F1CDx assay is be performed at Foundation Medicine, Inc. sites located in Cambridge, MA and Morrisville, NC.

We are pleased to inform you that the PMA supplement is approved. You may begin commercial distribution of the device in accordance with the conditions of approval described below. Although this letter refers to your product as a device, please be aware that some approved products may instead be combination products. The Premarket Approval Database located at

The sale and distribution of this device is restricted to prescription use in accordance with 21 CFR 801.109 and under section 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act (the act). FDA has determined that these restrictions on sale and distribution are necessary to provide reasonable assurance of the safety and effectiveness of the device. Your device is therefore a restricted device subject to the requirements in sections 502(q) and (r) of the act, in addition to the many other FDA requirements governing the manufacture, distribution, and marketing of devices.

Continued approval of the PMA is contingent upon the submission of periodic reports, required under 21 CFR 814.84, at intervals of one year (unless otherwise specified) from the date of approval of the original PMA. This report, identified as "Annual Report" and bearing the applicable PMA reference number, should be submitted to the address below. The Annual Report should indicate the beginning and ending date of the period covered by the report and should include the information required by 21 CFR 814.84.

In addition to the above, and in order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, the Annual Report must include, separately for each model number (if applicable), the number of devices sold and distributed during the reporting period, including those distributed to distributors. The distribution data will serve as a denominator and provide necessary context for FDA to ascertain the frequency and prevalence of adverse events, as FDA evaluates the continued safety and effectiveness of the device.

You have agreed to provide the following non-clinical information in a report, which may be followed by a PMA supplement where applicable.

1. Provide supplemental analytical accuracy data by testing an additional 20-25 cholangiocarcinoma samples which are FGFR2 rearrangement positive and comparing the results to those obtained with an externally validated orthogonal method.
2. Provide data from a study evaluating the effect of interfering substances to include Hemoglobin, Triglycerides and Bilirubin (conjugated and unconjugated).
3. Provide the results of a site-to-site reproducibility study to include the second laboratory site in Research Triangle Park (RTP), North Carolina using the same representative sample panel as was evaluated in support of the single site in Cambridge, Massachusetts. The study should include the same panel representation and testing strategy as was reviewed in the PMA.
4. Submit a PMA supplement that supports BIP updates to v3.3.x and BIP and that supporting software components’ migration to cloud service that do not impact the safety and effectiveness of your device.

Be advised that failure to comply with any post-approval requirement, including the analytical concordance study, interfering substances study and site-to-site reproducibility study, constitutes grounds for FDA withdrawal of approval of the PMA in accordance with 21 CFR 814.82(c).

This is a reminder that as of September 24, 2014, class III devices are subject to certain provisions of the final Unique Device Identification (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR
801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, 21 CFR 814.84 (b)(4) requires PMA annual reports submitted after September 24, 2014, to identify each device identifier currently in use for the subject device, and the device identifiers for devices that have been discontinued since the previous periodic report. It is not necessary to identify any device identifier discontinued prior to December 23, 2013. Combination Products may also be subject to UDI requirements (see 21 CFR 801.30). For more information on these requirements, please see the UDI website, https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-udi-system.

Before making any change affecting the safety or effectiveness of the PMA device, you must submit a PMA supplement or an alternate submission (30-day notice) in accordance with 21 CFR 814.39. All PMA supplements and alternate submissions (30-day notice) must comply with the applicable requirements in 21 CFR 814.39. For more information, please refer to the FDA guidance document entitled, "Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process" https://www.fda.gov/media/81431/download.

You are reminded that many FDA requirements govern the manufacture, distribution, and marketing of devices. For example, in accordance with the Medical Device Reporting (MDR) regulation, 21 CFR 803.50 and 21 CFR 803.52 for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products, you are required to report adverse events for this device. Manufacturers of medical devices, including in vitro diagnostic devices, are required to report to FDA no later than 30 calendar days after the day they receive or otherwise becomes aware of information, from any source, that reasonably suggests that one of their marketed devices:

1. May have caused or contributed to a death or serious injury; or
2. Has malfunctioned and such device or similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

Additional information on MDR, including how, when, and where to report, is available at https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems and on combination product postmarketing safety reporting is available at (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products).

In accordance with the recall requirements specified in 21 CFR 806.10 for devices or the postmarketing safety reporting requirements (21 CFR 4, Subpart B) for combination products, you are required to submit a written report to FDA of any correction or removal of this device initiated by you to: (1) reduce a risk to health posed by the device; or (2) remedy a violation of the act caused by the device which may present a risk to health, with certain exceptions specified in 21 CFR 806.10(a)(2). Additional information on recalls is available at https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/industry-guidance-recalls.

CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. CDRH will notify the public of its decision to approve your PMA by making available, among other information, a summary of the safety and effectiveness data
upon which the approval is based. The information can be found on the FDA CDRH Internet HomePage located at
requests for this information can also be made to the Food and Drug Administration, Dockets Management
Branch, (HFA-305), 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The written request should
include the PMA number or docket number. Within 30 days from the date that this information is placed on
the Internet, any interested person may seek review of this decision by submitting a petition for review under
section 515(g) of the act and requesting either a hearing or review by an independent advisory committee.
FDA may, for good cause, extend this 30-day filing period.

Failure to comply with any post-approval requirement constitutes a ground for withdrawal of approval of a
PMA. The introduction or delivery for introduction into interstate commerce of a device that is not in
compliance with its conditions of approval is a violation of law.

You are reminded that, as soon as possible and before commercial distribution of your device, you must
submit an amendment to this PMA submission with a copy of all final labeling. Final labeling that is
identical to the labeling approved in draft form will not routinely be reviewed by FDA staff when
accompanied by a cover letter stating that the final labeling is identical to the labeling approved in draft
form. If the final labeling is not identical, any changes from the final draft labeling should be highlighted and
explained in the amendment.

All required documents should be submitted, unless otherwise specified, to the address below and should
reference the above PMA number to facilitate processing.

    U.S. Food and Drug Administration
    Center for Devices and Radiological Health
    Document Control Center - WO66-G609
    10903 New Hampshire Avenue
    Silver Spring, MD 20993-0002

If you have any questions concerning this approval order, please contact Dun Liang at 301-796-3169 or
Dun.Liang@fda.hhs.gov.

Sincerely,

    Reena Philip -S

Reena Philip, Ph.D.
Director
Division of Molecular Genetics and Pathology
OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health